News & Trends - Biotechnology

BioMarin reveals new data for haemophilia gene therapy

Health Industry Hub | June 22, 2020 |
[Total: 1    Average: 4/5]

Biotech News: BioMarin announced new data from its phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for severe haemophilia A.

The results were presented during a late-breaking oral presentation at the World Federation of Haemophilia (WFH) Virtual Summit by Professor John Pasi, M.B., Ch.B., Ph.D., from Barts and the London School of Medicine and Dentistry and Chief Investigator for this Phase 1/2 study. 

“With four years of data, this study represents the longest duration of clinical experience for any gene therapy in haemophilia A.  It is exciting to observe that all study participants remain off Factor VIII prophylaxis therapy, while also experiencing a greater than 90% reduction in bleeding episodes from a single administration of valoctocogene roxaparvovec,” said Professor Pasi. “These data demonstrate the very real potential of a paradigm shift in the treatment of haemophilia A and that ongoing research into gene therapies could represent an entirely new way to approach meeting the high unmet need in patients with severe haemophilia A.”

“BioMarin is committed to the bleeding disorders community with the most robust and advanced clinical development program for a potential first gene therapy in severe haemophilia A,” said Hank Fuchs, M.D., President, Global Research and Development at BioMarin. “We are pleased to share these data at WFH.  Demonstrating a 96% reduction in exogenous Factor VIII usage as patients are now producing their own endogenous factor VIII is a potential benefit that we hope to be able to offer as we work closely with regulators to seek approval and work to reduce the burden of haemophilia.”

Register-and-join-Health-Industry-Hub-Pharma-MedTech-Biotech

The data presented at WFH is the most current data (April 8, 2020, cut off) and includes four years of data for the 6e13 vg/kg cohort and three years of data for the 4e13 vg/kg cohort. 


About the author

About the author

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Nam luctus finibus scelerisque. Nunc bibendum ipsum sed augue fringilla fringilla. Nullam at consectetur leo. Praesent viverra rutrum porta. Quisque vitae mi vel purus vulputate tincidunt. Class aptent taciti sociosqu ad litora torquent per conubia nostra, per inceptos himenaeos. Suspendisse et mi quis nisi rhoncus feugiat at ac tellus. Sed aliquam sodales nulla ac auctor. Sed pretium lobortis purus accumsan ullamcorper. Phasellus sodales vel odio in lobortis. Duis maximus sagittis bibendum. Interdum et malesuada fames ac ante ipsum primis in faucibus. Nunc dictum tincidunt ipsum in vestibulum. Donec ut sem consectetur, aliquam quam vitae, pharetra orci. Nam egestas non velit eu rhoncus. Duis congue neque non lacus tincidunt porta. Vestibulum ultricies pulvinar sem, molestie congue dui aliquet non.
  • Ut imperdiet leo id lorem fermentum consectetur.
  • Ut vitae orci et dui varius tincidunt.
  • Ut id magna non libero vestibulum pharetra ac faucibus nulla.
Aliquam erat volutpat. Vestibulum vitae varius diam. Nulla eget congue ante. Nunc ullamcorper sagittis augue vel dictum. Mauris finibus nibh ut pulvinar auctor. Vestibulum ut faucibus nisi. Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Quisque porta tortor ac justo malesuada elementum. Nulla tellus ante, cursus nec ex sit amet, suscipit bibendum arcu. Duis posuere orci dui, et mollis enim dictum at. Sed ullamcorper, sapien ut vulputate viverra, sem purus porttitor tellus, nec mattis mauris ligula sed risus. Nulla sagittis id ipsum eu mattis. Link to full profile

News & Trends - Biotechnology

Biotech News - New consortium to drive Australia’s regenerative medicine future

New consortium to drive Australia’s regenerative medicine future

Health Industry Hub | October 28, 2020 |

Please log in to Health Industry Hub to view this content.
More


News & Trends - Biotechnology

Biotech News - New Board member elected for AusBiotech

New Board member elected for AusBiotech

Health Industry Hub | October 28, 2020 |

Please log in to Health Industry Hub to view this content.
More


News & Trends - Pharmaceuticals

Pharma News - AbbVie collaborates with BioCurate to commercialise Australian early stage discoveries

AbbVie collaborates with BioCurate to commercialise Australian early stage discoveries

Health Industry Hub | October 28, 2020 |

Please log in to Health Industry Hub to view this content.
More


Digital & Innovation

Healthcare Technology Digital Innovations - The big ethical questions for AI in healthcare

The big ethical questions for AI in healthcare

Health Industry Hub | October 28, 2020 |

Digital & Innovation: The use of Artificial Intelligence (AI) is advancing in every area of healthcare. It is influencing the […]

More